Carolien Bierman
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Journal: Nature medicine
Published: April 11, 2022
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 06, 2020
Challenges in sentinel node pathology in the era of adjuvant treatment.
Journal: Journal of surgical oncology
Published: September 21, 2019
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Journal: The American journal of surgical pathology
Published: June 18, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Journal: The Lancet. Oncology
Published: December 24, 2018
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.
Journal: The British journal of surgery
Published: November 21, 2018
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 30, 2018
Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 29, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026